Join to View Full Profile
3855 Health Sciences DriveMC 0960La Jolla, CA 92093
Phone+1 858-822-6600
Fax+1 858-822-6844
Dr. Tzachanis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 2000 - 2003
Aristotle University of Thessaloniki School of MedicineClass of 1997
Certifications & Licensure
CA State Medical License 2012 - 2026
MA State Medical License 2003 - 2018
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation Start of enrollment: 2019 Nov 26
Publications & Presentations
PubMed
- A prospective clinical trial of GVHD prophylaxis with Post-Transplant Cyclophosphamide and Abatacept.Divya Koura, Kaitlyn C Dykes, Aaron Michael Goodman, Caitlin L Costello, Carolyn Mulroney
Blood Advances. 2025-06-24 - A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503).Brian A Jonas, Samantha C Fisch, Peter T Curtin, Gary J Schiller, Deepa Jeyakumar
Leukemia Research. 2025-06-02 - Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia.Athalia R Pyzer, Laura W Dillon, Elad Sharon, Theodore G Karrison, Yuanyuan Zha
Blood Advances. 2025-05-13
Abstracts/Posters
- Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...Dimitrios Tzachanis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...Dimitrios Tzachanis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematolo...Dimitrios Tzachanis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
UC San Diego Health Begins Treating Multiple Myeloma with CAR T-cell TherapyJune 3rd, 2021
Dr. Tzachanis on Data with Lisocabtagene Maraleucel in LymphomaFebruary 28th, 2020
Cancer Cell Therapy Success Grows, but Hospitals Struggle with CostOctober 4th, 2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
